Day: August 9, 2024

PARIS, Aug. 09, 2024 (GLOBE NEWSWIRE) — As the official partner of the Chinese Artistic Swimming Team, Cosmo Lady, a leading Chinese intimate wear brand, is sharing in this glory in its own unique way. Starting from August 5th, a stylish bus themed in the official brand color “Cosmo Pink” has been touring iconic landmarks in Paris, such as Eiffel Tower and the L’Arc de Triomphe. This initiative has not only instilled a deep sense of pride among Chinese fans abroad, but also garnered unanimous praise from audiences both at home and abroad. Following Olympic gold medalists Pan Zhanle and Zheng Qinwen, the Chinese Artistic Swimming Team has made history by winning China’s first-ever Olympic gold medal in artistic swimming! This historic breakthrough has ignited a wave of national pride and excitement, with...

Tokyo, Japan and Cambridge, UK, 9 August 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2024. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “The reception we have received to our new name, branding and evolved strategy from all our stakeholders has been fantastic. In transitioning from Sosei Heptares to Nxera Pharma, we are united under a single identity with a clear purpose to become a leading technology driven biopharmaceutical company bringing new medicines to patients in Japan and globally. “In Japan, we have made good progress building sales for PIVLAZ® alongside preparing for its commercialization in South Korea, with launch expected in 2025....

Suominen Corporation’s Half-Year Financial Report on August 9, 2024, at 9:30 a.m. (EEST) Suominen Corporation’s Half-Year Financial Report for January 1 – June 30, 2024: Gradual improvement continued KEY FIGURES  4-6/ 4-6/ 1-6/ 1-6/ 1-12/  2024 2023 2024 2023 2023Net sales, EUR million 118.7 112.7 232.3 229.5 450.9Comparable EBITDA, EUR million 5.0 2.7 9.5 5.3 15.8Comparable EBITDA, % 4.2 2.4 4.1 2.3 3.5EBITDA, EUR million 3.8 -1.9 8.4 0.7 11.2EBITDA, % 3.2 -1.7 3.6 0.3 2.5Comparable operating profit, EUR million 0.4 -2.1 0.3 -4.1 -2.8Comparable operating profit, % 0.3 -1.9 0.1 -1.8 -0.6Operating profit, EUR million -0.8 -6.7 -0.7 -8.8 -7.5Operating profit, % -0.7 -6.0 -0.3 -3.8 -1.7Profit for the period, EUR million -1.9 -8.2 -2.9 -12.1 -12.8Cash flow from operations, EUR million 2.1 6.4 -0.1 9.7 30.7Cash...

Mowi ASA hereby invites you to the presentation of the results for the second quarter 2024 at Scandic Flesland Airport hotel in Bergen, Norway in connection with the event “Vestland på Børs”. The results will be presented in English through a live webcast followed by a Q&A session. Participants will have the opportunity to submit questions online throughout the webcast session. The webcast will be available on http://www.mowi.com/investors/reports/ A recording of the webcast will be made available on our website immediately afterwards. Please note that the quarterly report and presentation will be published at 06:30 (CET).This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at an offering price of $6.50 per share, for total gross proceeds of approximately $60.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Zevra. All of the common stock is being offered by Zevra. The offering is expected to close on August 12, 2024, subject to customary closing conditions. In addition, Zevra has granted the underwriters a 30-day option to purchase up to an additional 1,384,615 shares of its common stock at the public offering price, less underwriting discounts and commissions. Cantor and William Blair are acting as joint book-running...

BROOKLYN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) — Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “VACHU” beginning August 9, 2024. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “VACH” and “VACHW”, respectively. The underwriters have been granted a 45-day option to purchase up to an additional 3,300,000 units offered by the Company to cover over-allotments, if any. The offering is expected to close on August 12, 2024,...

VANCOUVER, British Columbia, Aug. 08, 2024 (GLOBE NEWSWIRE) — MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) announces that as a result of a review by the British Columbia Securities Commission, the Company is issuing the following news release to clarify the Company’s disclosure. Acquisition of Healthcare Accretion Group Inc. (“HAG”) Acquisition of HAG On July 14, 2023, the Company announced that it had entered into a binding letter of intent with HAG providing for the acquisition of a 40% interest in HAG upon the initial closing and two subsequent options to acquire the remaining 60% interest (the “HAG Acquisition”). The Company would like to clarify that the letter of intent was non-binding, except as it related to certain fundamental provisions. During the course of negotiating...